The AMR innovation programme is led by Healthcare Innovation Consortium with partners, including Mecomed and Barts Life Sciences, and aims to fast-track new technologies that tackle AMR into the health sector.
Applications for the 2024 programme are now closed.
The challenge
AMR occurs when bacteria, viruses, fungi and parasites no longer respond to the drugs used to treat the infections they cause. AMR is recognised by the World Health Organization as one of the biggest threats to global health.
The UK government’s aim is to contain AMR by 2040. However, this depends on research and exploring new ways of monitoring AMR stewardship, and there is currently a lack of innovation.
Programme overview
The two-month programme starts in January 2024 and will provide six companies with solutions to address AMR with:
- In-depth insights into the NHS and Middle East markets
- Engagement with academic and clinical experts in the field
- Expert advice on regulation and compliance in both markets
- Facilitated connections on a national and international level
- Support to secure investment where applicable.
Criteria
HIC are seeking technologies that:
1) Support optimal use of antibiotics in clinical practice
2) Manage infection prevention and control
3) Support the identification of resistance bacteria
Aimed at:
Health Technology companies in the UK and Ireland and the Middle East that 1) have a solution that is or could be reapplied to AMR and 2) at least Technology Readiness Level 5, i.e. has had some basic validation in a real world environment.
Timeline:
Applications: 30 October – 1 December 2023 (Applications are now closed)
Briefing: 15 November 2023, 12-1pm (GMT)
Interviews: 10 – 12 January 2024
Programme duration: 5 February – 5 April 2024
